Healthcare Active Stocks: Pfizer Inc. (NYSE:PFE), Abbott Laboratories (NYSE:ABT), Zogenix Inc. (NASDAQ:ZGNX), Boston Scientific (NYSE:BSX)

Trading in Pfizer Inc. (NYSE:PFE) was halted last week because of pending news. While we see that all the time in smaller biotechs, MannKind will likely be halted next week during an FDA advisory committee meeting. Pfizer Inc. (NYSE:PFE) stock performance was 0.85% in last session and finished the day at $32.18. Traded volume was 62.72million shares in the last session and the average volume of the stock remained 25.23million shares. The beta of the stock remained 0.67. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

Abbott Laboratories (NYSE:ABT)‘s stock had its “buy” rating restated by Jefferies Group in a research note issued on Wednesday, AR Network reports. Abbott Laboratories (NYSE:ABT) dropped -1.23 percent to $38.339 Friday on volume of 21.66million shares. The intra-day range of the stock was $38.36 to $39.60. Abbott Laboratories (NYSE:ABT) has a market capitalization of $59.24billion.

Zogenix Inc. (NASDAQ:ZGNX) has traded like a company that is about to implode. Its highly controversial Zohydro has been getting inquiries into how it was approved for marketing despite an FDA panel being against the recommendation. Zogenix, Inc. (NASDAQ:ZGNX)’s stock on Mar 21, 2014 reported a decrease of -4.12% to the closing price of $3.26. Its fifty two weeks range is $1.25-$5.19. The total market capitalization recorded $454.90million. The overall volume in the last trading session was 14.62million shares. In its share capital, Zogenix, Inc. (NASDAQ:ZGNX) has 104.68million outstanding shares.

Boston Scientific Corporation (NYSE:BSX) sales starts to revive. To the surprise of many investors and market observors, the company’s revenues are wakening again, and its share price has more than doubled. On Friday, shares of Boston Scientific Corporation (NYSE:BSX) dropped -2.14% to close the day at $12.82. Company return on investment (ROI) is 2.10% and its monthly performance is recorded as -3.10%. Boston Scientific Corporation (NYSE:BSX) quarterly revenue growth is 11.09%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone